Atara Biotherapeutics Inc (NASDAQ:ATRA) Holdings Raised by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 22.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 8,800 shares of the biotechnology company’s stock after purchasing an additional 1,600 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Atara Biotherapeutics were worth $356,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Bank of Montreal Can increased its holdings in shares of Atara Biotherapeutics by 6.2% during the fourth quarter. Bank of Montreal Can now owns 5,183 shares of the biotechnology company’s stock worth $180,000 after buying an additional 302 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Atara Biotherapeutics by 5.1% during the first quarter. SG Americas Securities LLC now owns 10,432 shares of the biotechnology company’s stock worth $415,000 after buying an additional 503 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Atara Biotherapeutics by 12.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,554 shares of the biotechnology company’s stock worth $181,000 after buying an additional 512 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Atara Biotherapeutics by 6.2% during the fourth quarter. Legal & General Group Plc now owns 16,809 shares of the biotechnology company’s stock worth $584,000 after buying an additional 983 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Atara Biotherapeutics by 5.6% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,905 shares of the biotechnology company’s stock worth $657,000 after buying an additional 999 shares in the last quarter.

ATRA has been the subject of several research analyst reports. ValuEngine downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 17th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. BidaskClub downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 30th. Finally, Mizuho reiterated a “buy” rating and set a $62.00 price target on shares of Atara Biotherapeutics in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $40.40.

In related news, CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction on Friday, March 29th. The stock was sold at an average price of $38.66, for a total value of $301,548.00. Following the completion of the sale, the chief executive officer now directly owns 332,243 shares in the company, valued at $12,844,514.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joe Newell sold 1,500 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $39.96, for a total value of $59,940.00. Following the completion of the sale, the insider now owns 63,646 shares of the company’s stock, valued at $2,543,294.16. The disclosure for this sale can be found here. Insiders sold 36,150 shares of company stock valued at $1,147,091 over the last 90 days. 10.60% of the stock is currently owned by company insiders.

NASDAQ ATRA opened at $22.05 on Friday. Atara Biotherapeutics Inc has a twelve month low of $21.31 and a twelve month high of $47.22. The company has a quick ratio of 9.96, a current ratio of 9.96 and a debt-to-equity ratio of 0.05.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $0.04. On average, sell-side analysts predict that Atara Biotherapeutics Inc will post -5.54 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics Inc (NASDAQ:ATRA) Holdings Raised by DekaBank Deutsche Girozentrale” was first published by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://theenterpriseleader.com/2019/06/14/atara-biotherapeutics-inc-nasdaqatra-holdings-raised-by-dekabank-deutsche-girozentrale.html.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: How to find the components of the quick ratio

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.